Back
Neurocrine Biosciences Quote, Financials, Valuation and Earnings
Buy
60
NBIX
Neurocrine Biosciences
Last Price:
142.31
Seasonality Move:
6.24%
7 Day Trial
ALL ACCESS PASS
$
7
Neurocrine Biosciences Price Quote
$142.31
+0.02 (+0.28%)
(Updated: May 18, 2024 at 5:49 AM ET)
Neurocrine Biosciences Key Stats
Buy
60
Neurocrine Biosciences (NBIX)
is a Buy
Day range:
$140.51 - $142.86
52-week range:
$89.04 - $148.37
Dividend yield:
0%
P/E ratio:
57.61
P/S ratio:
7.31
P/B ratio:
6%
Volume:
639.9K
Avg. volume:
746.1K
1-year change:
49.35%
Market cap:
$14.3B
Revenue:
$1.9B
EPS:
$3.63
How Much Does Neurocrine Biosciences Make?
-
How Much Are Neurocrine Biosciences's Sales Annually?
NBIX Revenues are $1.9B -
How Much Profit Does Neurocrine Biosciences's Make A Year?
NBIX net income is $249.7M
Is Neurocrine Biosciences Growing As A Company?
-
What Is Neurocrine Biosciences's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.23% -
What Is Neurocrine Biosciences's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Neurocrine Biosciences Stock Price Performance
-
Did Neurocrine Biosciences Stock Go Up Last Month?
Neurocrine Biosciences share price went up by 6.8% last month -
Did NBIX's Share Price Rise Over The Last Year?
NBIX share price rose by 49.35% over the past 1 year
What Is Neurocrine Biosciences 52-Week High & Low?
-
What Is Neurocrine Biosciences’s 52-Week High Share Price?
Neurocrine Biosciences has traded as high as $148.37 over the past 52 weeks -
What Is Neurocrine Biosciences’s 52-Week Low Share Price?
Neurocrine Biosciences has traded as low as $89.04 over the past 52 weeks
Neurocrine Biosciences Price To Free Cash Flow
-
Is Neurocrine Biosciences Stock Overvalued?
Neurocrine Biosciences is trading at a price to free cash flow ratio of 23.57 -
Is Neurocrine Biosciences Stock Undervalued?
Neurocrine Biosciences EV to Free Cash Flow ratio is 21.76 -
What Is Neurocrine Biosciences’s Price Earnings Growth Ratio?
NBIX PEG ratio is 0.08 -
Is Neurocrine Biosciences Trading At A Premium To Earnings?
Neurocrine Biosciences EV to EBIT ratio is 28.16
Is It Risky To Buy Neurocrine Biosciences?
-
How Much Debt Does Neurocrine Biosciences Have?
Total long term debt quarterly is $259M -
How Much Cash Does Neurocrine Biosciences Have?
Cash and short term investments quarterly total is $1.2B -
What Is Neurocrine Biosciences’s Book Value Per Share?
Book value per share is 23.72
Is Neurocrine Biosciences Cash Flow Positive?
-
What Is NBIX Cash Flow From Operations?
Cash flow from operations (TTM) is $645.4M -
What Is Neurocrine Biosciences’s Cash Flow From Financing?
Cash flow from financing (TTM) is $127M -
What Is Neurocrine Biosciences’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$480M
Neurocrine Biosciences Return On Invested Capital
-
Is Management Doing A Good Job?
NBIX return on invested capital is 16.66% -
What Is Neurocrine Biosciences Return On Assets?
ROA measures how assets are converting to revenues and is 12.71% -
What Is NBIX Return On Equity?
ROE is a measure of profitability and is 18.2%
Neurocrine Biosciences Earnings Date & Stock Price
-
What Is Neurocrine Biosciences's Stock Price Today?
A single share of NBIX can be purchased today for 142.29 -
What Is Neurocrine Biosciences’s Stock Symbol?
Neurocrine Biosciences trades on the nasdaq under the ticker symbol: NBIX -
When Is Neurocrine Biosciences’s Next Earnings Date?
The next quarterly earnings date for Neurocrine Biosciences is scheduled on August 1, 2024 -
When Is NBIX's next ex-dividend date?
Neurocrine Biosciences's next ex-dividend date is May 26, 2020 -
How To Buy Neurocrine Biosciences Stock?
You can buy Neurocrine Biosciences shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Neurocrine Biosciences Competitors
-
Who Are Neurocrine Biosciences's Competitors?
Below is a list of companies who compete with Neurocrine Biosciences or are related in some way:
Neurocrine Biosciences Dividend Yield
Data Unavailable
Neurocrine Biosciences Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | -6.81% |
| Revenue: | 22.57% | 0.64% |
Analyst Recommendations
| Buy Recommendations: | 17 |
|---|---|
| Hold Recommendations: | 6 |
| Sell Recommendations: | 0 |
| Price Target: | 158.43 |
| Upside from Last Price: | 11.34% |